Private sector health care major Apollo Hospitals has revealed its plans to set up 200 clinics across the country, to provide a comprehensive diabetes management solution.

On Saturday, the company launched two diabetes management clinics under the brand name 'Sugar' on pilot basis in Hyderabad.

The latest launched clinics will provide comprehensive diagnosis and evaluation, education, and treatment, including life-style support to the diabetics.

Further, the clinics will also offer year-long disease management programme, including controlling blood sugar level and early intervention for complications of diabetes.

One of the largest API manufacturers in Asia, Aurobindo Pharma Limited, has secured final approval from the US Food & Drug Administration (USFDA) to manufacture and market Didanosine Delayed Release (Enteric-Coated) Capsules 125mg, 200mg, 250mg and 400mg.

Didanosine Delayed Release Capsules is the generic version of Bristol Myer Squibb's Videx EC (Didanosine) Delayed-release Capsules and is indicated for the treatment of HIV-1 infections in combination with other antiretroviral in adults.

Stock market analysts have maintained ‘buy’ rating on Ranbaxy Laboratories stock with an intraday target of Rs 312. 

According to them, interested traders can purchase the stock above Rs 308 with a strict stop loss of Rs 300. If the stock market remains positive, the stock pricing becomes more attractive, and reach above Rs 315. 
 

Atlas Laboratories and Pharmaceuticals Ltd has made announcement that the company is foraying into the Over-The-Counter (OTC) segment as it envisages to diversify its overall product portfolio up to 100 drugs by year 2009. 

While commenting on the plans, Mr. Ashwin Kapur, Executive Director of Atlas Laboratories and Pharmaceuticals (ALP) stated, “From the beginning of the next fiscal, we would have around 80-100 products under our portfolio and out of which 10-15 would be in the category of OTC segments.”

Domestic Drug-maker Lupin, acquired 60 percent stakes in South Africa-based Pharma Dynamics. The amount of deal is not disclosed by the company. It is the third acquisition by the company. Earlier in July, Lupin took over the German drug maker Hormosan Pharma and captured most of shares of Generic Health, Australia in August. 

Ranbaxy would hire the services of Giuliani Partners to deal with the situation arising, after the banning of some of its products in the US market. It is recalled that the US Food and Drug Administration is not satisfied with the product quality of many of its drugs. It has, earlier banned 31 drugs in the US market. The Indian drug maker Ranbaxy is a major supplier of drugs to the US market.